The DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Genome-Informed Targeted Therapy for Osteosarcoma
Open accessAbstract
Osteosarcoma is a highly aggressive cancer for which treatment has remained essentially unchanged for more than 30 years. Osteosarcoma is characterized by widespread and recurrent somatic copy-number alterations (SCNA) and structural rearrangements. In contrast, few recurrent point mutations in protein-coding genes have been identified, suggesting that genes within SCNAs are key oncogenic drivers in this disease. SCNAs and structural rearrangements are highly heterogeneous across osteosarcoma cases, suggesting the need for a genome-informed approach to targeted therapy. To identify patient-specific candidate drivers, we used a simple heuristic based on degree and rank order of copy-number amplification (identified by whole-genome sequencing) and changes in gene expression as identified by RNA sequencing. Using patient-derived tumor xenografts, we demonstrate that targeting of patient-specific SCNAs leads to significant decrease in tumor burden, providing a road map for genome-informed treatment of osteosarcoma. Significance: Osteosarcoma is treated with a chemotherapy regimen established 30 years ago. Although osteosarcoma is genomically complex, we hypothesized that tumor-specific dependencies could be identified within SCNAs. Using patient-derived tumor xenografts, we found a high degree of response for “genome-matched” therapies, demonstrating the utility of a targeted genome-informed approach. This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the paitients with metastatic disease either at diagnosis or at the time of recurrence portends a dismal prognosis with 5-year survival of only 20-30% [8].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“This genomic complexity has long been interpreted as a sign of chromosomal instability but emerging data suggest that the mechanisms triggering complexity are active early in the process of malignant transformation 35,37 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“These rearrangements give rise to genome-wide copy number alterations, usually dominated by copy number loss, including of PTEN and CDKN2A/B, but with recurrent amplifications of MYC, VEGFA and CCNE1 (ref.35 ).”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Of note, the resulting complex genomes are subsequently maintained with some fidelity, even from diagnosis to relapse 35,37 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Copy number amplifications of potentially targetable genes seemed to predict sensitivity to specific agents 35 ; however, subsequent work has shown that the picture is much more complicated 9 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Recurrent CDK4 alterations have been described in osteosarcoma 35 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Furthermore, current molecular research continues to classify osteosarcomas not by histological appearance via classical osteosarcoma pathological descriptions but by proteo-genomic drivers of disease that provide further insight into disease biology and may have both prognostic and therapeutic implications 35 .”
From Osteosarcoma (2022) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEMPreprint
Li, H. (2013) · arXiv (Cornell University) · doi:10.48550/arxiv.1303.3997 · Cited by 10,154
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Landscape of transcription in human cells
Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012) · Nature · doi:10.1038/nature11233 · Cited by 5,187
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEMPreprint
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 5,155
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,926
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
DELLY: structural variant discovery by integrated paired-end and split-read analysis
Rausch, T., Zichner, T., Schlattl, A., Stütz, A. M., Beneš, V., & Korbel, J. O. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts378 · Cited by 2,438
Cited by
Sorted by citations
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Zhou, Y., Yang, D., Yang, Q., Lv, X., Huang, W., Zhou, Z., Wang, Y., Zhang, Z., Yuan, T., Ding, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20059-6 · Cited by 672
New Horizons in the Treatment of Osteosarcoma
Meltzer, P. S., & Helman, L. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2103423 · Cited by 672
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Molecular Biology of Osteosarcoma
Czarnecka, A. M., Synoradzki, K. J., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. L. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 343
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
Future Directions in the Treatment of Osteosarcoma
Smrke, A., Anderson, P. M., Gulia, A., Gennatas, S., Huang, P. H., & Jones, R. L. (2021) · Cells · doi:10.3390/cells10010172 · Cited by 225
Improving human cancer therapy through the evaluation of pet dogs
LeBlanc, A. K., & Mazcko, C. N. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0297-3 · Cited by 207
Jiang, Y., Wang, J., Sun, M., Zuo, D., Wang, H., Shen, J., Jiang, W., Mu, H., Ma, X., Yin, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34689-5 · Cited by 159
TP53 in bone and soft tissue sarcomas
Thoenen, E. A., Curl, A., & Iwakuma, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.010 · Cited by 140
Suehara, Y., Alex, D., Bowman, A., Middha, S., Zehir, A., Chakravarty, D., Wang, L., Jour, G., Nafa, K., Hayashi, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4032 · Cited by 135
Gardner, H. L., Sivaprakasam, K., Briones, N., Zismann, V., Perdigones, N., Drenner, K., Facista, S., Richholt, R., Liang, W., Aldrich, J., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0487-2 · Cited by 120
Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer · doi:10.1002/cncr.32351 · Cited by 127
Molecular mechanisms underpinning sarcomas and implications for current and future therapy
Damerell, V., Pepper, M. S., & Prince, S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00647-8 · Cited by 120
Wei, H., Chen, F., Chen, J.-Y., Lin, H., Wang, S., Wang, Y., Wu, C., Lin, J., & Zhong, G. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s372851 · Cited by 109
Targeted therapy for osteosarcoma: a review
Li, S., Zhang, H., Liu, J., & Shang, G. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04614-4 · Cited by 107
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
Ma, H., Seebacher, N. A., Hornicek, F. J., & Duan, Z. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.022 · Cited by 98
Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution
Valle-Inclán, J. E., Noon, S. D., Trevers, K. E., Elrick, H., van Belzen, I. A. E. M., Zumalave, S., Sauer, C. M., Tanguy, M., Butters, T., Muyas, F., et al. (2025) · Cell · doi:10.1016/j.cell.2024.12.005 · Cited by 105
Cillo, A. R., Mukherjee, E., Bailey, N. G., Onkar, S., Daley, J. D., Salgado, C. M., Li, X., Liu, D., Ranganathan, S., Burgess, M. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1471 · Cited by 91
Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy
Zhao, J., Dean, D. C., Hornicek, F. J., Yu, X., & Duan, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.020 · Cited by 92
Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90
Advances in targeted therapy for osteosarcoma based on molecular classification
Chen, Y., Liu, R., Wang, W., Wang, C., Zhang, N., Shao, X., He, Q., & Ying, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105684 · Cited by 86
Current Status and Prospects of Targeted Therapy for Osteosarcoma
Hu, Z., Wen, S., Huo, Z., Wang, Q., Zhao, J., Wang, Z., Chen, Y., Zhang, L., Zhou, F., Guo, Z., et al. (2022) · Cells · doi:10.3390/cells11213507 · Cited by 78
Self-citationImmune-related prognosis biomarkers associated with osteosarcoma microenvironment
Hong, W., Yuan, H., Gu, Y., Liu, M., Ji, Y., Huang, Z., Yang, J., & Ma, L. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1165-7 · Cited by 69
An update on emerging drugs in osteosarcoma: towards tailored therapies?
Hattinger, C. M., Patrizio, M. P., Magagnoli, F., Luppi, S., & Serra, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1654455 · Cited by 67
The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response
Cascini, C., & Chiodoni, C. (2021) · Cells · doi:10.3390/cells10071668 · Cited by 63
Ge, X., Liu, W., Zhao, W., Feng, S., Duan, A., Ji, C., Shen, K., Liu, W., Zhou, J., Jiang, D., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.025 · Cited by 63
Targeting the VEGF Pathway in Osteosarcoma
Assi, T., Watson, S., Samra, B., Rassy, E., Cesne, A. L., Italiano, A., & Mir, O. (2021) · Cells · doi:10.3390/cells10051240 · Cited by 62
RETRACTED: Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma
Feng, W., Dean, D. C., Hornicek, F. J., Spentzos, D., Hoffman, R. M., Shi, H., & Duan, Z. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920922055 · Cited by 57
RetractedLeBlanc, A. K., Mazcko, C. N., Cherukuri, A., Berger, E. P., Kisseberth, W. C., Brown, M. E., Lana, S. E., Weishaar, K. M., Flesner, B. K., Bryan, J. N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0315 · Cited by 55
Edmunds, G. L., Smalley, M. J., Beck, S., Errington, R. J., Gould, S., Winter, H. R., Brodbelt, D. C., & O'Neill, D. G. (2021) · Canine Medicine and Genetics · doi:10.1186/s40575-021-00100-7 · Cited by 50
Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas
Menéndez, S. T., Gallego, B., Murillo, D., Rodríguez, A., & Rodrı́guez, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122621 · Cited by 48
Fibroblast Activation Protein Expression in Sarcomas
Crane, J. N., Graham, D. S., Mona, C. E., Nelson, S. D., Samiei, A., Dawson, D. W., Dry, S., Masri, M. G., Crompton, J. G., Benz, M., et al. (2023) · Sarcoma · doi:10.1155/2023/2480493 · Cited by 46
Mannheimer, J., Tawa, G. J., Gerhold, D. L., Braisted, J. C., Sayers, C. M., McEachron, T. A., Meltzer, P. S., Mazcko, C. N., Beck, J. A., & LeBlanc, A. K. (2023) · Communications Biology · doi:10.1038/s42003-023-05208-z · Cited by 52
Schott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0873 · Cited by 47
Self-citationWhat’s new in bone forming tumours of the skeleton?
Franceschini, N., Lam, S. W., Cleton-Jansen, A., & Bovée, J. V. M. G. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02683-w · Cited by 44
Shah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Straessler, K., Kurtz, D. M., Leung, S. G., Spillinger, A., Liu, H.-Y., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0987 · Cited by 42
Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor
Slotkin, E. K., Bowman, A. S., Levine, M. F., Cruz, F. S. D., Coutinho, D. F., Sanchez, G. D. I., Rosales, N., Modak, S. I., Tap, W. D., Gounder, M. M., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0722 · Cited by 42
Lietz, C. E., Newman, E. T., Kelly, A. D., Xiang, D. H., Zhang, Z., Luscko, C. A., Lozano‐Calderón, S. A., Ebb, D. H., Raskin, K. A., Cote, G. M., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03117-1 · Cited by 44
Fleuren, E. D. G., Vlenterie, M., & van der Graaf, W. T. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1013359 · Cited by 41
de Nonneville, A. T., Salas, S., Bertucci, F., Sobinoff, A. P., Adélaı̈de, J., Guillé, A., Finetti, P., Noble, J. R., Churikov, D., Chaffanet, M., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215859 · Cited by 39
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
Landuzzi, L., Manara, M. C., Lollini, P.-L., & Scotlandi, K. (2021) · Cells · doi:10.3390/cells10020416 · Cited by 39
Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis
Nirala, B. K., Yamamichi, T., & Yustein, J. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411367 · Cited by 42
MAFG-driven osteosarcoma cell progression is inhibited by a novel miRNA miR-4660
Shan, H., Zhu, L., Yao, C., Zhang, Z.-Q., Liu, Y.-Y., Jiang, Q. L., Zhou, X., Wang, X., & Cao, C. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.03.006 · Cited by 38
Liu, M., Liu, F., Li, Y., Yin, J., Gao, Y., Wang, X., Yang, C., Liu, J., & Li, H.-J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5040326 · Cited by 36
Wang, Y., Tian, X., Zhang, W., Zhang, Z., Lazcano, R., Hingorani, P., Roth, M. E., Gill, J. D., Harrison, D. J., Xu, Z., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0836 · Cited by 37
Díaz, E. C. G., Lee, A. G., Sayles, L. C., Feria, C., Sweet-Cordero, A., & Yang, F. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200768 · Cited by 35
Self-citationReceptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
Albarrán, V., Villamayor, M. L., Chamorro, J., Rosero, D. I., Pozas, J., Román, M. S., Calvo, J. C., de Aguado, P. P., Moreno, J. A., Guerrero, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213784 · Cited by 37
Switchable CAR T cell strategy against osteosarcoma
Hidalgo, L., Somovilla-Crespo, B., Garcia-Rodriguez, P., Morales‐Molina, Á., Rodríguez-Milla, M. Á., & Garcı́a-Castro, J. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03437-z · Cited by 35
Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment
Koo, J., Hayashi, M., Verneris, M. R., & Lee‐Sherick, A. B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581107 · Cited by 34
MYC amplifications are common events in childhood osteosarcoma
Noon, S. D., Ijaz, J., Coorens, T. H. H., Amary, F. M., Ye, H., Strobl, A., Lyskjær, I., Flanagan, A. M., & Behjati, S. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.219 · Cited by 34
Rajan, S., Ringwalt, E. M., McAloney, C. A., Vetter, T. A., Cam, M., Gross, A. C., Taslim, C., Wang, M., Cannon, M. V., Oles, A. R., et al. (2023) · BMC Biology · doi:10.1186/s12915-023-01593-3 · Cited by 44
Zhra, M., Akhund, S. A., & Mohammad, K. S. (2025) · Pharmaceuticals · doi:10.3390/ph18040520 · Cited by 37
Aberrant RNA Splicing Is a Primary Link between Genetic Variation and Pancreatic Cancer Risk
Tian, J., Chen, C., Rao, M., Zhang, M., Lu, Z., Cai, Y., Ying, P., Li, B., Wang, H., Wang, L., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4367 · Cited by 29
Cai, M., Li, X., Xu, M., Zhou, S., Fan, L., Huang, J., Xiao, C., Lee, Y., Yang, B., Wang, L., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.138086 · Cited by 34
Marinoff, A. E., Spurr, L. F., Fong, C., Li, Y. Y., Forrest, S. J., Ward, A., Doan, D., Corson, L., Mauguen, A., Pinto, N. R., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00334 · Cited by 45
Direct transposition of native DNA for sensitive multimodal single-molecule sequencing
Nanda, A. S., Wu, K., Irkliyenko, I., Woo, B., Ostrowski, M. S., Clugston, A. S., Sayles, L. C., Xu, L., Satpathy, A. T., Nguyen, H. G., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01748-0 · Cited by 36
Self-citationSmeester, B. A., Slipek, N. J., Pomeroy, E. J., Laoharawee, K., Osum, S. H., Larsson, A. T., Williams, K. B., Stratton, N. C., Yamamoto, K., Peterson, J. J., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115353 · Cited by 33
Rajan, S., Zaccaria, S., Cannon, M. V., Cam, M., Gross, A. C., Raphael, B. J., & Roberts, R. D. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0348 · Cited by 32
Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma
Kinnaman, M. D., Zaccaria, S., Makohon-Moore, A. P., Arnold, B., Levine, M. F., Gundem, G., Ossa, J. A., Głodzik, D., Rodriguez-Sanchez, I., Bouvier, N., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0385 · Cited by 31
Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma
Yan, P., Wang, J., Yue, B., & Wang, X. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189171 · Cited by 31
Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities
Du, X., Wei, H., Zhang, B., Wang, B., Li, Z., Pang, L. K., Zhao, R., & Yao, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1117867 · Cited by 31
The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers
Tu, C., Ren, X., He, J., Zhang, C., Chen, R., Wang, W., & Li, Z. (2019) · Journal of Cancer · doi:10.7150/jca.35113 · Cited by 30
Schott, C. R., Shah, A. T., & Sweet-Cordero, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_1 · Cited by 30
Self-citationRecent Advances in Pediatric Cancer Research
McEachron, T. A., & Helman, L. J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1191 · Cited by 35
LncRNA MALAT1-related signaling pathways in osteosarcoma
Farzaneh, M., Najafi, S., Anbiyaee, O., Azizidoost, S., & Khoshnam, S. E. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02876-x · Cited by 30
Nirala, B. K., Patel, T. D., Kurenbekova, L., Shuck, R. L., Dasgupta, A., Rainusso, N. C., Coarfa, C., & Yustein, J. T. (2023) · JCI Insight · doi:10.1172/jci.insight.164947 · Cited by 30
Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma
Wei, R., Thanindratarn, P., Dean, D. C., Hornicek, F. J., Guo, W., & Duan, Z. (2020) · Journal of Orthopaedic Research® · doi:10.1002/jor.24659 · Cited by 29
Zhang, W., Zhao, W., Li, Q., Zhao, D., Qu, J., Yuan, Z., Cheng, Z., Zhu, X., Zhuang, X., & Zhang, Z. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01012-1 · Cited by 30
A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma
Zheng, D., Xia, K., Yu, L., Gong, C., Shi, Y., Li, W., Qiu, Y., Yang, J. M., & Guo, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.699212 · Cited by 27
Das, S., Idate, R., Regan, D. P., Fowles, J. S., Lana, S. E., Thamm, D. H., Gustafson, D. L., & Duval, D. L. (2021) · Communications Biology · doi:10.1038/s42003-021-02683-0 · Cited by 29
Sun, X., Zheng, D., & Guo, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.835014 · Cited by 26
PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
Mancarella, C., Morrione, A., & Scotlandi, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216346 · Cited by 28
Wang, J., Ferrena, A., Zhang, R., Singh, S., Viscarret, V., Al-Harden, W., Aldahamsheh, O., Borjihan, H., Singla, A. K., Yaguare, S., et al. (2024) · Oncogene · doi:10.1038/s41388-024-02942-4 · Cited by 25
The Clinical Implications of Tumor Mutational Burden in Osteosarcoma
Xie, L., Yang, Y., Guo, W., Che, D., Xu, J. H., Sun, X., Liu, K., Ren, T., Liu, X., Yang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.595527 · Cited by 28
Zhang, Y., Li, Z., Wei, J., Kong, L., Song, M., Zhang, Y., Xiao, X., Cao, H., & Jin, Y. (2022) · Medicine · doi:10.1097/md.0000000000031055 · Cited by 27
Discovery of VH domains that allosterically inhibit ENPP1
Solomon, P. E., Bracken, C. J., Carozza, J. A., Wang, H., Young, E. P., Wellner, A., Liu, C. C., Sweet-Cordero, A., Li, L., & Wells, J. A. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01368-5 · Cited by 28
Sarcoma as a Model for Adolescent and Young Adult Care
Reed, D. R., Naghavi, A. O., & Binitie, O. T. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00684 · Cited by 27
Makielski, K. M., Sarver, A. L., Henson, M. S., Stuebner, K., Borgatti, A., Suksanpaisan, L., Preusser, C., Tăbăran, F., Cornax, I., O’Sullivan, M. G., et al. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.100736 · Cited by 26
Challenges of Systemic Therapy Investigations for Bone Sarcomas
Nakano, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073540 · Cited by 25
IL-11Rα-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma
Jiang, J., Wang, R., Yang, L., Sha, Y., Zhao, S., Guo, J., Chen, D., Zhong, Z., & Meng, F. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.048 · Cited by 26
Yang, J., Fu, Q., Jiang, H., Li, Y., & Liu, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1022973 · Cited by 27
Yi, X., Wang, Y., & Xu, S. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-01967-1 · Cited by 23
The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma
Wang, J., Aldahamsheh, O., Ferrena, A., Borjihan, H., Singla, A. K., Yaguare, S., Singh, S., Viscarret, V., Tingling, J., Zi, X., et al. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14578 · Cited by 22
Identification of mitochondrial RNA polymerase as a potential therapeutic target of osteosarcoma
Han, Q., Zhang, X.-Y., Yan, P., Chen, S., Liu, F., Zhu, Y.-R., & Tian, Q. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00780-x · Cited by 24
Loss of RanGAP1 drives chromosome instability and rapid tumorigenesis of osteosarcoma
Gong, Y., Zou, S., Deng, D., Wang, L., Hu, H., Qiu, Z., Wei, T., Yang, P., Zhou, J., Zhang, Y., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2022.12.012 · Cited by 24
Fan, D., Zhang, C., Wang, H., Wei, Q., Cai, H., Wei, F., Bian, Z., Liu, W., Wang, X., & Liu, Z. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100683 · Cited by 26
Is there a role for chemotherapy after local relapse in high‐grade osteosarcoma?
Palmerini, E., Torricelli, E., Cascinu, S., Pierini, M., PAOLIS, M. D., Donati, D. M., Cesari, M., Longhi, A., Abate, M. E., Paioli, A., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27792 · Cited by 24
The Targeted Therapies for Osteosarcoma via Six Major Pathways
Wang, S., Ren, Q., Li, G., Zhao, X., Zhao, X., & Zhang, Z. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230821142839 · Cited by 24
Castillo‐Tandazo, W., Mutsaers, A. J., & Walkley, C. R. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00534-w · Cited by 23
Koshkina, N., Yang, Y., & Kleinerman, E. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_12 · Cited by 25
Peck, B., Bland, P. J., Mavrommati, I., Muirhead, G., Cottom, H., Wai, P. T., Maguire, S. L., Barker, H. E., Morrison, E., Kriplani, D., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1822 · Cited by 24
Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
Assi, A., Farhat, M., Hachem, M. C. R., Zalaquett, Z., Aoun, M., Daher, M., Sebaaly, A., & Kourié, H. R. (2023) · Journal of bone oncology · doi:10.1016/j.jbo.2023.100511 · Cited by 25
LncRNA LINC00588 Suppresses the Progression of Osteosarcoma by Acting as a ceRNA for miRNA-1972
Zhou, F.-C., Zhang, Y., Liu, H., Song, J. L., & Shao, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00255 · Cited by 23
Self-citationPharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact
Hattinger, C. M., Patrizio, M. P., Luppi, S., & Serra, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134659 · Cited by 23
Pearson, A. D., Gaspar, N., Janeway, K., Campbell-Hewson, Q., Lawlor, E. R., Copland, C., Karres, D., Norga, K., Benzaghou, F., Weiner, S., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.008 · Cited by 22
Self-citationLuce, A., Lama, S., Chacon-Millan, P., Itro, A., Sangiovanni, A., Caputo, C., Ferranti, P., Cappabianca, S., Caraglia, M., & Stiuso, P. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3337013 · Cited by 22
Regulation of Molecular Targets in Osteosarcoma Treatment
Çelik, B., Cicek, K., Leal, A. F., & Tomatsu, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012583 · Cited by 22
Tan, J., Yang, B., Zhong, H., Luo, M., Su, Z., Xie, C. L., Shi, M., Sun, C., & Lin, L. (2023) · Biomarker Research · doi:10.1186/s40364-022-00442-9 · Cited by 22
Metadata
- Authors
- Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., Hazard, F. K., Spunt, S. L., Marina, N., Kim, G. E., Cho, S.-J., Avedian, R. S., Mohler, D. G., Kim, M.-O., DuBois, S. G., Hawkins, D. S., & Sweet-Cordero, E. A.
- Affiliations
- University of California, San Francisco (US)
- 1Division of Hematology and Oncology, Department of Pediatrics, University of California, San Francisco, California.
- Stanford Medicine (US)
- Harvard University (US)
- Seattle Children's Hospital (US)
- ORCID
- Venue
- Cancer Discovery
- Published
- 2019-01-01
- Volume
- 9
- Issue
- 1
- Pages
- 46-63
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7134333
- OpenAlex
- W2892650455
- Cited by
- 452
- References
- 78
- Citations by year
- 2026: 48 · 2025: 59 · 2024: 67 · 2023: 84 · 2022: 63 · 2021: 63 · 2020: 52 · 2019: 14
- FWCI
- 24.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- HHS | National Institutes of Health (NIH) (S10OD018220, P30CA082103, 2T32OD011121-11, R25 CA180993-02)
- Hyundai Motor Group | Hyundai Motor America | Hyundai Hope On Wheels (Hope On Wheels)
- Stanford University School of Medicine (Stanford School of Medicine, Stanford University) (Morgridge Scholar Grant)
- St. Baldrick's Foundation (Team Clarkie)
- CureSearch for Children's Cancer
- Sarcoma Foundation of America (SFA)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- osteosarcoma, somatic copy number alterations, structural rearrangement, targeted therapy, patient-derived xenografts, copy number amplification, gene expression changes, oncogenic drivers
- MeSH terms
- Whole Genome Sequencing, Animals, Bone Neoplasms, Humans, Osteosarcoma, Sequence Analysis, RNA, Xenograft Model Antitumor Assays, Genomics, Mice, Genomic Structural Variation, DNA Copy Number Variations, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
